A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
|Articles|September 24, 2018
- September 2018 Immunization
- Volume 84
- Issue 9
Improving Patients' Understanding of the Clinical Benefit of EPA and DHA Omega-3s
Author(s)David J. Foreman, RPh, ND
Advertisement
FACULTY
David J. Foreman, RPh, ND Author/Medical Expert Herbal Pharmacist Palm Harbor, Florida
EDUCATIONAL OBJECTIVES:
At the completion of this activity, the participant will be able to:
- Explain the mechanism and disease states in which omega-3 supplementation has been shown to have positive outcomes
- Identify the recommended dose of omega-3s for specific patients and disease states
- Examine and understand common barriers to patient utilization of omega-3 supplements
TARGET AUDIENCE: Retail pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: September 10, 2018
EXPIRATION DATE: September 10, 2019
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
almost 8 years ago
The Waiting Is the Hardest Partabout 8 years ago
New and Novel HIV Medicationsabout 8 years ago
Self-Care for Respiratory Issuesabout 8 years ago
States Continue to Expand Availability of Telehealthabout 8 years ago
Educating Patients About the Dangers of Sharing Rx Medicationsabout 8 years ago
When Complying With a Law Enforcement Request Causes Problemsabout 8 years ago
Pharmacists Play a Key Role in Counseling Patients About ProbioticsAdvertisement
Related to this article
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Intensive Chemotherapy in Combination With Quizartinib Versus Midostaurin for FLT3-ITD Mutated Acute Myeloid Leukemia: A Multicenter Cohort Study
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
4
First-Line HIV Therapy: Integrase Inhibitors, Exceptions, and HLA-B*5701 Testing
5